EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer

Pedro Cruz iD, Cristina Boixareu iD, Diogo J Silva iD, Joshua Ting iD, Rayssa Sena iD, Steph A Pang iD, Stephanie Mullings iD, Anna Minchom iD

Cancers · 09.03.2026 · 18 (5) · 880

DOI: 10.3390/cancers18050880 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.03.2026. Verfasst von Pedro Cruz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5GP, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-oncogene-addicted non-small cell lung cancer therapy has seen major advances in recent years. New molecular targets and biomarkers have enabled the development of drugs as diverse as immunotherapies and antibody–drug conjugates, among others. With a pharmacological armamentarium so precise, phase I trials have also evolved from exclusively toxicological studies into early efficacy signal-seeking trials. Nonetheless, difficulties remain, with the frequent failure of new drugs when progressing to a phase III setting. Challenges are seen in the setting of later lines therapy (testing against docetaxel), of which there are several examples. These are being tackled with promising new drugs being developed, based on innovative biological rationales. We review the current state of the art of drug development in non-oncogene-addicted non-small cell lung cancer, including advances, new drugs and targets, challenges, and opportunities in drug development.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatescarcinomaclinical trialsdrug developmentimmunotherapynon-oncogene-addicted non-small cell lung cancernon-small-cell lung

Autor:innen und Institutionen

  • Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5GP, UK.

ORCID-Profile: Pedro Cruz, Cristina Boixareu, Diogo J Silva, Joshua Ting, Rayssa Sena, Steph A Pang, Stephanie Mullings, Anna Minchom

Zitieren

APA

Cruz, P., Boixareu, C., Silva, D. J., Ting, J., Sena, R., Pang, S. A., Mullings, S., & Minchom, A. (2026). Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers, 18(5), 880. https://doi.org/10.3390/cancers18050880

Vancouver

Cruz P, Boixareu C, Silva DJ, Ting J, Sena R, Pang SA, et al. Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers. 2026;18(5):880. doi:10.3390/cancers18050880

BibTeX
@article{Cruz2026,
  author = {Cruz, Pedro and Boixareu, Cristina and Silva, Diogo J and Ting, Joshua and Sena, Rayssa and Pang, Steph A and Mullings, Stephanie and Minchom, Anna},
  title = {Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {880},
  doi = {10.3390/cancers18050880}
}
Kostenlos starten →